Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

The Zacks Analyst Blog Highlights: Gilead, BNY Mellon, State Street, Alliant Energy And Dillard's

Published 02/28/2018, 10:01 PM
Updated 07/09/2023, 06:31 AM

For Immediate Release

Chicago, IL – March 1, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Gilead (NASDAQ:GILD) , BNY Mellon (NYSE:BK) , State Street (NYSE:STT) , Alliant Energy (NYSE:LNT) and Dillard's (NYSE:DDS) .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday’s Analyst Blog:

Top Analyst Reports for Gilead, BNY Mellon and State Street

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Gilead, BNY Mellon and State Street. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Gilead’s shares have outperformed the Zacks Biotech industry in the last six months, increasing +6.1% vs. a decline of -4.6%. Gilead topped both earnings and revenue estimates in the fourth quarter.

The HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the United States and EU. The TAF-based regimens now represent 62% of total HIV prescription volume following the launch of Genvoya, Odefsey and Descovy in 2016.

The Zacks analyst thinks that the approval of Gilead’s latest triple HIV therapy is likely to provide an impetus to the stock as Gilead is now banking on its HIV franchise and newer avenues like the CAR-T therapy. However, the HCV franchise is under tremendous pressure due to lower patient starts and increasing competition.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Both pricing and market share are expected to stabilize by mid-2018 while patient starts are expected to decline further. The company’s guidance for 2018 also lacks luster.

(You can read the full research report on Gilead here >>>).

Shares of BNY Mellon have underperformed the Zacks Major Regional Banks industry in the last six months (+11.3% vs. +21.6%). The company’s earnings surpassed expectations in only two of the trailing four quarters. Concentration risk arising from significant dependence on fee-based income remains a matter of concern for the company.

If there are any changes in individual investment preferences, regulatory amendments or a slowdown in capital market activities, it could hurt the company’s financials. However, The Zacks analyst thinks easing margin pressure (driven by gradual higher interest rates) and rising loan demand will drive revenue growth. Also, potential lesser regulations, lower tax rates and cost-saving initiatives are likely to drive profitability.

(You can read the full research report on BNY Mellon here >>>).

State Street’s shares have underperformed the Zacks Major Regional Banks industry in the last six months (+16.5% vs. +21.6%). The company has an impressive earnings surprise history, having surpassed expectations in each of the trailing four quarters.

The Zacks analyst likes its new business wins, synergies from GE Asset Management deal and rising interest rates, all of which are likely to continue supporting profitability. Further, the company’s cost saving efforts through multi-year restructuring plan is expected to a success.

However, continuous decline in trading services revenues is a concern. Also, mounting expenses remain a major near-term concern for the company.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

(You can read the full research report on State Street here >>>).

Other noteworthy reports we are featuring today include Alliant Energy and Dillard's.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook (NASDAQ:FB): https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.



Alliant Energy Corporation (LNT): Free Stock Analysis Report

Bank Of New York Mellon Corporation (The) (BK): Free Stock Analysis Report

State Street Corporation (STT): Free Stock Analysis Report

Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Dillard's, Inc. (DDS): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.